Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention.
Data from the 5 large randomized, double-blind, placebo-controlled trials that used glycoprotein IIb/IIIa inhibitors during percutaneous transluminal coronary angioplasty were pooled for a total of 10,691 patients. We found that the use of glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions significantly decreases the need for unplanned stenting for abrupt closure.
Bhatt
D L
DL
Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195, USA.
Lincoff
A M
AM
Kereiakes
D J
DJ
Tcheng
J E
JE
Simoons
M L
ML
van der Wieken
L R
LR
Godfrey
N
N
Califf
R M
RM
Topol
E J
EJ
D015906:Angioplasty, Balloon, Coronary; D003327:Coronary Disease / Q000628:therapy*; D006801:Humans; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000627:therapeutic use*; D015607:Stents; D016896:Treatment Outcome
D019039:Platelet Glycoprotein GPIIb-IIIa Complex